Immune Hepatitis — Liver Inflammation From Immunotherapy

Immune hepatitis is almost always detected on a routine liver blood test, not by how a patient feels. Before every immunotherapy cycle, your oncology team checks liver enzymes (ALT and AST) and bilirubin as part of standard monitoring recommended by NCCN and ASCO guidelines for managing immune-related adverse events. A rise in these numbers — even with no symptoms at all — is usually the first and only sign of immune hepatitis. This is why liver monitoring before each cycle is treated as non-negotiable rather than optional: it is the main way this reaction is caught early, well before it could cause noticeable harm.

In most people, no — immune hepatitis produces no symptoms at all in its early stages, which is exactly why blood test monitoring matters so much. When symptoms do appear, they usually mean the inflammation has progressed further, and can include yellowing of the eyes or skin, dark urine, unusually pale stools, new and unexplained itching, loss of appetite, nausea, or discomfort under the right ribs. Extreme, out-of-pattern tiredness can also occur. None of these should be watched and waited on at home — call your oncology team, or CION's helpline, the same day any of them appear.

In the large majority of cases, yes. When immune hepatitis is caught early through routine blood tests and managed promptly — usually by pausing immunotherapy and, if the elevation is significant, starting corticosteroid treatment under oncology supervision — liver function typically returns to normal over several weeks. Many patients are later able to resume immunotherapy, sometimes at a different pace or with closer monitoring, once liver values have settled and a tumour board has weighed the benefit against the risk. Severe cases that are ignored or caught late can cause lasting liver damage, which is the main reason routine monitoring and same-day reporting of symptoms both matter.

There is no fixed day, but immune-related hepatitis most often appears within the first few months of treatment, commonly somewhere around the second to fourth cycle, according to general patterns described in NCCN and ASCO guidance on immune-related adverse events. It can occur earlier, later, or — less commonly — even after immunotherapy has been stopped altogether, which is why liver monitoring and awareness of symptoms continue for as long as your oncology team recommends, not just during active treatment. Because the timing varies, the routine blood test before every cycle matters more than trying to predict when it might happen.

Contact your oncology team the same day the result comes back, even if you feel completely well — most immune hepatitis has no symptoms at this stage. Do not start any liver 'detox' supplement, herbal remedy, or over-the-counter medicine on your own, and avoid alcohol until your team has reviewed the result, since these can make interpretation harder or worsen liver strain. Your oncologist will typically repeat the test, assess how high the numbers are, and decide whether immunotherapy needs to be paused while the cause is confirmed. Reporting promptly, rather than waiting for a scheduled visit, is what keeps this manageable.

Not reliably on your own — the visible signs, such as yellow eyes or dark urine, can look identical whether the cause is immunotherapy, a viral infection, a medication, or a pre-existing liver condition. Only blood tests and a clinical assessment by your oncology team can tell these apart, sometimes alongside tests to rule out viral hepatitis or other causes. Because the correct treatment is different for each cause, never assume it is 'just jaundice' or self-treat at home — get evaluated by your oncology team the same day any of these signs appear, so the right cause is identified quickly.